Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Expert Opin Biol Ther. 2008 Dec;8(12):1955-62. doi: 10.1517/14728220802517901 .

    N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility.

    Source

    University of Melbourne, Department of Clinical and Biomedical Sciences, Barwon Health, PO Box 281, Geelong 3220, Victoria, Australia. seetald@barwonhealth.org.au

    Abstract

    BACKGROUND:

    Glutathione is an endogenous antioxidant and has a ubiquitous role in many of the body's defences. Treatment with N-acetylcysteine (NAC) has been shown to increase levels of glutathione. NAC has been proposed as a treatment for several illnesses.

    OBJECTIVES:

    The efficacy and tolerability of NAC was examined across a range of conditions to evaluate the evidence supporting the use of NAC for each indication.

    METHODS:

    A literature search was conducted using PubMed. Information was also collected from other online sources including the websites of the Therapeutic Goods Administration of Australia and the FDA.

    RESULTS:

    Reports ranged from case studies to clinical trials. There is strong evidence to support the use of NAC for the treatment of paracetamol overdose and emerging evidence suggesting it has utility in psychiatric disorders, particularly schizophrenia and bipolar disorder. NAC is safe and well tolerated when administered orally but has documented risks with intravenous administration.

    PMID:
    18990082
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Informa Healthcare

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk